SideChannel (SDCH) 10-Q16 May 142014 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Mar. 31, 2014	1-May-14
Document And Entity Information	'	'
Entity Registrant Name	'NATIONAL SCIENTIFIC CORP/AZ	'
Entity Central Index Key	'0001022505	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--09-30	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	248,256,722
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

Balance_Sheets_Unaudited

Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Sep. 30, 2013
CURRENT ASSETS:	'	'
Cash	$7,656	$8,587
Accounts receivables	5,176	8,338
Total current assets	12,832	16,925
Software, net	701,611	817,921
TOTAL ASSETS	714,443	834,846
CURRENT LIABILITIES:	'	'
Accounts payables and accrued expenses	699,559	361,994
Liabilities attributed to discontinued operations	42,873	35,356
Lines of credit	87,041	9,796
Total current liabilities	829,473	407,146
TOTAL LIABILITIES	829,473	407,146
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding	40,000	40,000
Common stock, $0.01 par value, 650,000,000 shares authorized; 246,829,216 and 214,624,216 issued and outstanding	2,468,292	2,146,242
Additional paid-in capital	25,214,828	24,783,723
Accumulated deficit	-27,838,150	-26,542,265
Total stockholders' equity (deficit)	-115,030	427,700
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$714,443	$834,846

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Statement of Financial Position [Abstract]	'	'
Preferred Stock, Par Value	$0.01	$0.01
Preferred Stock, Shares Authorized	4,000,000	4,000,000
Preferred Stock, Shares Issued	4,000,000	4,000,000
Preferred Stock, Shares Outstandng	4,000,000	4,000,000
Common Stock, Par Value	$0.01	$0.01
Common Stock, Shares Authorized	650,000,000	650,000,000
Common Stock, Shares Issued	246,829,216	214,624,216
Common Stock, Shares Outstanding	246,829,216	214,624,216

Statements_of_Operations_Unaud

Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
Statements of Operations (Unaudited) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'	'	'
REVENUES	$105,118	$174,214	$222,675	$323,571
COST OF REVENUES	61,155	61,155	122,310	121,160
GROSS PROFIT	43,963	113,059	100,365	202,411
OPERATING EXPENSES:	'	'	'	'
Selling, general and administrative	1,106,142	224,454	1,328,218	343,325
Research and development	30,000	55,000	60,000	95,000
Total operating expenses	1,136,142	279,454	1,388,218	438,325
Gain on the disposal of assets	'	1,353	'	1,353
OPERATING LOSS	-1,092,179	-165,042	-1,287,853	-234,561
OTHER INCOME (EXPENSE)	'	'	'	'
Interest expense	-279	-69	-515	-196
Total other income expense	-279	-69	-515	-196
LOSS FROM CONTINUING OPERATIONS	-1,092,458	-165,111	-1,288,368	-234,757
INCOME (LOSS) FROM DISCONTINUED OPERATIONS	3,198	-38	-7,517	58,946
NET LOSS	($1,089,260)	($165,149)	($1,295,885)	($175,811)
Basic and diluted	'	'	'	'
Continuing operations	$0	$0	($0.01)	$0
Discontinued operations	$0	$0	$0	$0
Total	$0	$0	($0.01)	$0
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING	'	'	'	'
Basic and diluted	224,546,327	212,756,568	219,656,908	212,472,748

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
Statements of Cash Flows (Unaudited) (USD $)	Mar. 31, 2014		Mar. 31, 2013
Statement of Cash Flows [Abstract]	'		'
Net Loss	($1,295,885)		($175,811)
Income from discontinued operations	-7,517		58,946
Loss from continuing operations	-1,288,368		-234,757
Adjustments to reconcile net loss from continuing operations to net cash from operating activities:	'		'
Depreciation and amortization	122,310		121,160
Common stock issued for compensation	666,750		28,155
Common stock issued for software sales	5,700		9,350
Gain on the disposal of assets	'		1,353
Changes in operating assets and liabilities:	'		'
Accounts receivable	3,162		3,012
Accounts payable and accrued expenses	397,270		88,638
Net cash (used in) provided by operating activities	-93,176		14,205
CASH FLOWS FROM INVESTING ACTIVITIES:	'		'
Proceeds from the sale of assets	'		1,353
Net cash provided by investing activities	'		1,353
CASH FLOWS FROM FINANCING ACTIVITIES:	'		'
Repayment of advances from officer	'		-25,591
Proceeds from line of credit	78,245		2,500
Repayment of line of credit	-1,000		-22,152
Common stock issued for cash	15,000		141,000
Net cash provided by financing activities	92,245		95,757
INCREASE (DECREASE) IN CASH	-931		111,315
CASH, BEGINNING OF PERIOD	8,587		51,356
CASH, END OF PERIOD	7,656		162,671
SUPPLEMENTAL DISCLOSURE	'		'
Interest paid	'		'
Taxes paid	'		'
NONCASH INVESTING AND FINANCING ACTIVITIES	'		'
Write-off of related party debt to additional paid-in capital	59,704	[1]	'	[1]
Common stock issued to purchase software	6,000		13,000
Accrual of software acquisition costs	'		$23,000

[1]	All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

1_DESCRIPTION_OF_BUSINESS

1. DESCRIPTION OF BUSINESS	6 Months Ended
1. DESCRIPTION OF BUSINESS	Mar. 31, 2014
Accounting Policies [Abstract]	'
1. DESCRIPTION OF BUSINESS	'
	NOTE 1- DESCRIPTION OF BUSINESS

	Cloud Medical Doctor Software Corporation (the “Company”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation.

	In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.

	In the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries and support to assist patients with their billing and insurance questions.

2_BASIS_OF_PRESENTATION_OF_INT

2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	6 Months Ended
2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
2. BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	'
	NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

	The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

	Operating results for the six months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending September 30, 2014. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended September 30, 2013 have been omitted; this report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2013 included within the Company’s Form 10-K as filed with the Securities and Exchange Commission.

3_GOING_CONCERN

3. GOING CONCERN	6 Months Ended
3. GOING CONCERN	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
3. GOING CONCERN	'
	NOTE 3 - GOING CONCERN

	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has recurring losses from operations and an accumulated deficit at March 31, 2014 of $27,838,150 and needs additional cash to maintain its operations.

	These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

4_SUMMARY_OF_SIGNIFICANT_ACCOU

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At March 31, 2014, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.

Impairment of Long-Lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The acquired software technologies are reviewed annually for impairment.

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

Fair value is focused on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

The three-level hierarchy for fair value measurements is defined as follows:

•

Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;

•

Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;

•

Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

At March 31, 2014

Software

—

701,611

Total Software

—

701,611

At September 30, 2013

Software

—

937,431

Total Software

—

937,431

Accounts Receivable and Allowance for Uncollectible Accounts

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of March 31, 2014 and 2013, the Company had no valuation allowance for the Company’s accounts receivable.

Income Taxes

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At March 31, 2014, the Company did not record any liabilities for uncertain tax positions.

Revenue Recognition

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.”

VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. In the first year and each year thereafter, the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

Transaction revenue is generated from the following services and recognized when a transaction occurs:

Electronic Remittance Advise $0.35 Electronic remittance transaction fee;

Paper Claims $1.00 Paper claim fee;

Carrier Direct $0.16 Carrier direct fee;

Fast Forward $0.35 Fast forward transaction fee; and,

Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

The Company had not received any transaction revenues in the three and six months ended March 31, 2014.

Cost of License, and Subscriptions Revenues

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license-based royalties during the three months ended March 31, 2014 and 2013.

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for customer support during the three months ended March 31, 2014 and 2013.

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired software technologies are amortized over their useful lives of 5 years.

Deferred Revenue

Deferred revenue result from fees billed to customers for which revenue has not yet been recognized or for which the conditions of the arrangement have been modified. The Company recognizes revenue to provide up-front capitalization to Cloud-MD for each provider added to the solution set. The Company also recognizes annual subscription fees for virtual servers and subscription and small usage fees and those revenues are based on a 48-month lease, Cloud-MD would amortize the revenue over the life of the agreement of 48 months. In addition, it features incremental monthly revenue, for the duration of the lease (48 months) based on fees assessed for transactions such as eligibility claims processing, etc. The Company has deferred revenue of $0 as of March 31, 2014.

Sales Commissions

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans which are established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $0 and $20,000 for the three months ended March 31, 2014 and 2013, respectively, and $37,000 and $40,260 for the six months ended March 31, 2014 and 2013, respectively.

Research and Development and Software Development Costs

Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred.

Share-Based Compensation

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award. Compensation cost is recognized over the vesting or requisite service period.

Basic and Diluted Net Income (Loss) per Common Share

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding. Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

The Company has 4,000,000 preferred shares that can be converted subject to the limitation of the Company’s authorized shares at 1 preferred share for 150 common shares. The conversion can only take place with the approval of the Board of Directors. At March 31, 2014, the preferred shares could be converted into 600,000,000 of common shares resulting in dilution of common shareholders. The preferred shares are anti-dilutive since the losses the Company has incurred for the periods ended March 31, 2014 and 2013.

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.

Concentration of Credit Risk

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

Subsequent Events

The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.

Recent Accounting Pronouncements

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

5_SOFTWARE

5. SOFTWARE	6 Months Ended
5. SOFTWARE	Mar. 31, 2014
Research and Development [Abstract]	'
5. SOFTWARE	'
	NOTE 5 – SOFTWARE

	The following is a detail of software at March 31, 2014 and September 30, 2013:

		31-Mar-14			September 30,
		31-Mar-14			2013

	Source Code License – Antree Systems Limited	$	6,000		$	—
	Encryption Software Code		15,800			15,800
	Source Code License – MediSouth, LLC		2,500			2,500
	Acquisition of Doctor’s Network of America		10,000			10,000
	Software License		1,200,106			1,200,106
	EMR Certification		23,000			23,000
	Total intangible assets		1,257,406			1,251,406
	Accumulated amortization of intangible assets		(545,795	)		(423,485	)
	Accumulated impairment of assets		(10,000	)		(10,000	)
	Total intangible assets	$	701,611		$	817,921

	The Company’s software was placed into service starting in the second quarter of fiscal year ended September 30, 2012. The amortization expense was $61,155 and $61,155 for the three months ended March 31, 2014 and 2013, respectively. The Company recognized a $0 and $6,000 for impairment of software acquired from Doctors Network of America (“DNA”) operating in Flowood, Mississippi during the six months ended March 31, 2014 and the year ended September 30, 2013, respectively. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the assets to be impaired.

	Source Code License

	In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

	Encryption Software Code

	On November 21, 2012, the Company purchased from CipherSmith, LLC a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.

	Doctors Network of America

	On June 22, 2012, the Company entered into an acquisition agreement that closed on March 16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (“Krooss”) for 500,000 shares of common stock. As of September 30, 2012, 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.

	Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000.

6_DISCONTINUED_OPERATIONS

6. DISCONTINUED OPERATIONS	6 Months Ended
6. DISCONTINUED OPERATIONS	Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
6. DISCONTINUED OPERATIONS	'
	NOTE 6- DISCONTINUED OPERATIONS

	The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the former business operation of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the specific consideration for this transaction.
	Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations. Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

	On March 16, 2013, the Company closed the acquisition with the final payment for DNA. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a lawsuit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believes the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations.

	Details of the classifications for net assets, liabilities and operations are shown below.

		March 31,			September 30,
		2014			2013

	Net liabilities of discontinued operations:
	Accounts payable	$	42,837		$	35,356
	Net liabilities of discontinued operations	$	42,837		$	35,356
		Three Months Ended
		March 31,
		2014			2013

	Discontinued operations:
	Revenues	$	53,766		$	900
	Cost of sales		—			—
	Operating expenses		(50,568	)		(938	)
	Gain from write-off of debt		—			—
	Income (loss) from discontinued operations	$	3,198		$	(38	)

		Six Months Ended
		March 31,
		2014			2013
	Discontinued operations:
	Revenues	$	131,050		$	900
	Cost of sales		—			—
	Operating expenses		(138,567	)		(938	)
	Gain from write-off of debt		—			58,984
	Income (loss) from discontinued operations	$	(7,517	)	$	58,946

7_LINES_OF_CREDIT

7. LINES OF CREDIT	6 Months Ended
7. LINES OF CREDIT	Mar. 31, 2014
Debt Disclosure [Abstract]	'
7. LINES OF CREDIT	'
	NOTE 7 – LINES OF CREDIT

	In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha in the amount of $65,000 at a 4.00% interest rate per annum which renews annually. As of March 31, 2014, the Company had borrowed $62,612 against the line of credit.

	The Company has a revolving line of credit with Chase Bank with a balance as of March 31, 2014 in the amount of $24,429 and a borrowing limit of $50,000. The line of credit with Chase Bank has an interest rate of 4.25% per annum and renews annually.

8_DEBT_MITIGATION_PROGRAM

8. DEBT MITIGATION PROGRAM	6 Months Ended
8. DEBT MITIGATION PROGRAM	Mar. 31, 2014
OTHER INCOME (EXPENSE)	'
8. DEBT MITIGATION PROGRAM	'
	NOTE 8 – DEBT MITIGATION PROGRAM

	The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during six months ended March 31, 2014 and 2013, the Company recognized a gain on the write-off of liabilities in the amount of $0 and $58,984 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $59,704 and $0 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.

	The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.

		Six Months Ended
		March 31,		March 31,
		2014		2013

	Debt Mitigation Program:
	Accounts payable and accrued expenses	$	59,704	$	58,984
	Accrued interest		—		—
	Total debt mitigation program	$	59,704	$	58,984
	Gain on write-off of debt	$	—	$	(58,984	)
	Additional paid-in capital (1)	$	59,704	$	—
	-1	All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

9_COMMITMENTS_AND_CONTINGENCIE

9. COMMITMENTS AND CONTINGENCIES	6 Months Ended
9. COMMITMENTS AND CONTINGENCIES	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
9. COMMITMENTS AND CONTINGENCIES	'
	NOTE 9 – COMMITMENTS AND CONTINGENCIES

	Rent expense for the three months and six ended March 31, 2014 and 2013 was $0 for all periods.

	The Company entered into an agreement to purchase the assets of DNA in June 2012 and after due diligence by both parties the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.

	The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will be terminate and shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.

	As discussed in Note 8, the Company has written off $59,704 and $58,984 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for the six months ended March 31, 2014 and 2013, respectively. However, the related creditors could make a claim in the future in regards to these liabilities.

10_RELATED_PARTY_TRANSACTIONS

10. RELATED PARTY TRANSACTIONS	6 Months Ended
10. RELATED PARTY TRANSACTIONS	Mar. 31, 2014
Related Party Transactions [Abstract]	'
10. RELATED PARTY TRANSACTIONS	'
	NOTE 10– RELATED PARTY TRANSACTIONS

	The Company repaid $0 and $25,591 of the advances from the Company’s CEO in the three months ended March 31, 2014 and 2013, respectively. The advances from the CEO are due on demand and do not accrue interest. As of March 31, 2014 and September 30, 2013, there were no amounts owed to the CEO for advances, respectively.

11_EQUITY

11. EQUITY	6 Months Ended
11. EQUITY	Mar. 31, 2014
Equity [Abstract]	'
11. EQUITY	'
	NOTE 11 - EQUITY

	As of March 31, 2014, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01.

	Six Months Ended March 31, 2014

	Stock Issued for Cash

	During the six months ended March 31, 2014, the Company issued 35,000 shares of common stock for $15,000 in net cash proceeds as follows:

	Date			Number of Shares			Proceeds

		21-Oct-13			25,000		$	5,000
		12-Jan-14			10,000		$	10,000
		Total			35,000		$	15,000

	Stock Issued in Connection with Software Licensing and Subscription Agreements

	During the six months ended March 31, 2014, the Company issued 220,000 shares of common stock valued at $5,700 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2014.

	Date			Number of Shares			Fair Value

		4-Dec-13			120,000		$	3,600
		4-Mar-14			100,000			2,100
		Total			220,000		$	5,700

	Stock Issued for Assets Acquisition

	In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

	In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares issued because the shares were lost during delivery to Antree Systems.

	Stock Issued for Services

	During the six months ended March 31, 2014, the Company issued 31,750,000 shares of common stock as compensation. The fair values of the shares were a total of $666,750 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

	Date			Number of Shares			Fair Value			Description of Services

		5-Mar-14			31,750,000		$	666,750			Compensation

		Total			31,750,000		$	666,750

	Six Months Ended March 31, 2013

	Stock Issued for Cash

	During the six months ended March 31, 2013, the Company issued 197,500 shares of common stock for $141,000 in net cash proceeds as follows:

	Date			Number of Shares			Proceeds

		14-Oct-12			20,000		$	20,000
		14-Oct-12			15,000			3,000
		14-Oct-12			18,750			2,500
		14-Oct-12			18,750			2,500
		6-Dec-12			15,000			3,000
		12-Mar-13			20,000			20,000
		12-Mar-13			20,000			20,000
		31-Mar-13			50,000			50,000
		27-Mar-13			20,000			20,000
		Total			197,500		$	141,000

	Stock Issued in Connection with Software Licensing and Subscription Agreements

During the six months ended March 31, 2013, the Company issued 300,000 shares of common stock valued at $9,350 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded as a reduction of software revenue recognized during the three months ended March 31, 2013.

Date			Number of Shares			Fair Value

	14-Oct-12			50,000		$	1,300
	6-Dec-12			100,000			2,800
	12-Mar-13			50,000			1,750
	21-Mar-13			50,000			1,750
	21-Mar-13			50,000			1,750
	Total			300,000		$	9,350

Stock Issued for Services

During the six months ended March 31, 2013, the Company issued 827,000 shares of common stock as compensation. The fair values of the shares were a total of $28,155 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

Date			Number of Shares			Fair Value			Description of Services

	14-Oct-12			10,000		$	260			Commission
	6-Dec-12			100,000			2,800			Compensation
	12-Mar-13			50,000			1,750			Consulting
	21-Mar-13			167,000			5,845			Compensation
	21-Mar-13			500,000			17,500			Compensation
	Total			827,000		$	28,155

Stock Issued for Assets Acquisition

During the six months ended March 31, 2013, the Company issued 400,000 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $13,000 based on the market price on the dates of grant.

Preferred Stock

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value and 4,000,000 are issued and outstanding as of September 30, 2013. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been granted to our CEO & CFO on November 30, 2010 and issued on April 11, 2012 which was valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

On December 17, 2013, the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice and approval of the Board of Directors. Presently, the holders of the Preferred A shares have not sent notice to the Board of Directors.

12_SUBSEQUENT_EVENTS

12. SUBSEQUENT EVENTS	6 Months Ended
12. SUBSEQUENT EVENTS	Mar. 31, 2014
Subsequent Events [Abstract]	'
12. SUBSEQUENT EVENTS	'
	NOTE 12 – SUBSEQUENT EVENTS

	Stock Issued for Services

	On April 21, 2014, the Company issued 1,407,506 shares of common stock as compensation. The fair values of the shares were a total of $21,253 and were recorded at the market price on the date of grant.

4_SUMMARY_OF_SIGNIFICANT_ACCOU1

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Use of Estimates and Assumptions

Cash and Cash Equivalents

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

The three-level hierarchy for fair value measurements is defined as follows:

•

Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;

•

Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2014 and September 30, 2013 for assets measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

At March 31, 2014

Software

—

701,611

Total Software

—

701,611

At September 30, 2013

Software

—

937,431

Total Software

—

937,431

Accounts Receivable and Allowance for Uncollectible Accounts

Income Taxes

Revenue Recognition

Transaction revenue is generated from the following services and recognized when a transaction occurs:

Electronic Remittance Advise $0.35 Electronic remittance transaction fee;

Paper Claims $1.00 Paper claim fee;

Carrier Direct $0.16 Carrier direct fee;

Fast Forward $0.35 Fast forward transaction fee; and,

Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

The Company had not received any transaction revenues in the three and six months ended March 31, 2014.

Cost of License, and Subscriptions Revenues

Deferred Revenue

Sales Commissions

Research and Development and Software Development Costs

Share-Based Compensation

Basic and Diluted Net Income (Loss) per Common Share

Concentration of Credit Risk

Subsequent Events

The Company has evaluated all transactions occurring between March 31, 2014 and through the date of issuance of the financial statements for subsequent event disclosure.

Recent Accounting Pronouncements

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

4_SUMMARY_OF_SIGNIFICANT_ACCOU2

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Mar. 31, 2014
Accounting Policies [Abstract]	'
Fair Value of Financial Instruments	'
		Level 1		Level 2		Level 3		Total
	At March 31, 2014
	Software	$	—	$	—	$	701,611	$	701,611
	Total Software	$	—	$	—	$	701,611	$	701,611

	At September 30, 2013
	Software	$	—	$	—	$	937,431	$	937,431
	Total Software	$	—	$	—	$	937,431	$	937,431

5_SOFTWARE_Tables

5. SOFTWARE (Tables)	6 Months Ended
5. SOFTWARE (Tables)	Mar. 31, 2014
Research and Development [Abstract]	'
Software	'
		31-Mar-14			September 30,
		31-Mar-14			2013

	Source Code License – Antree Systems Limited	$	6,000		$	—
	Encryption Software Code		15,800			15,800
	Source Code License – MediSouth, LLC		2,500			2,500
	Acquisition of Doctor’s Network of America		10,000			10,000
	Software License		1,200,106			1,200,106
	EMR Certification		23,000			23,000
	Total intangible assets		1,257,406			1,251,406
	Accumulated amortization of intangible assets		(545,795	)		(423,485	)
	Accumulated impairment of assets		(10,000	)		(10,000	)
	Total intangible assets	$	701,611		$	817,921

6_DISCONTINUED_OPERATIONS_Tabl

6. DISCONTINUED OPERATIONS (Tables)	6 Months Ended
6. DISCONTINUED OPERATIONS (Tables)	Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations	'
		March 31,			September 30,
		2014			2013

	Net liabilities of discontinued operations:
	Accounts payable	$	42,837		$	35,356
	Net liabilities of discontinued operations	$	42,837		$	35,356
		Three Months Ended
		March 31,
		2014			2013

	Discontinued operations:
	Revenues	$	53,766		$	900
	Cost of sales		—			—
	Operating expenses		(50,568	)		(938	)
	Gain from write-off of debt		—			—
	Income (loss) from discontinued operations	$	3,198		$	(38	)

		Six Months Ended
		March 31,
		2014			2013
	Discontinued operations:
	Revenues	$	131,050		$	900
	Cost of sales		—			—
	Operating expenses		(138,567	)		(938	)
	Gain from write-off of debt		—			58,984
	Income (loss) from discontinued operations	$	(7,517	)	$	58,946

8_DEBT_MITIGATION_PROGRAM_Tabl

8. DEBT MITIGATION PROGRAM (Tables)	6 Months Ended
8. DEBT MITIGATION PROGRAM (Tables)	Mar. 31, 2014
OTHER INCOME (EXPENSE)	'
Debt Mitigation Program	'
		Six Months Ended
		March 31,		March 31,
		2014		2013

	Debt Mitigation Program:
	Accounts payable and accrued expenses	$	59,704	$	58,984
	Accrued interest		—		—
	Total debt mitigation program	$	59,704	$	58,984
	Gain on write-off of debt	$	—	$	(58,984	)
	Additional paid-in capital (1)	$	59,704	$	—

3_GOING_CONCERN_Details_Narrat

3. GOING CONCERN (Details Narrative) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Accumulated Deficit	($27,838,150)	($26,542,265)

4_SUMMARY_OF_SIGNIFICANT_ACCOU3

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Software	$701,611	$937,431
Total Software	701,611	937,431
Level 1	'	'
Software	'	'
Total Software	'	'
Level 2	'	'
Software	'	'
Total Software	'	'
Level 3	'	'
Software	701,611	937,431
Total Software	$701,611	$937,431

4_SUMMARY_OF_SIGNIFICANT_ACCOU4

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2013
Accounting Policies [Abstract]	'	'	'	'	'
FDIC Insured Cash	$250,000	'	$250,000	'	'
Subscription Revenue, Year One	'	'	1,200	'	'
Subscription Revenue, Year Two	'	'	1,500	'	'
Subscription Revenue, Year Three	'	'	1,800	'	'
Subscription Revenue, Year Four	'	'	2,400	'	'
Deferred Revenue	0	'	0	'	'
Sales Commissions	$0	$20,000	$40,260	$37,000	'
Preferred Stock, Shares Outstanding	4,000,000	'	4,000,000	'	4,000,000
Preferred Stock converted into Common Stock, Shares Common Stock	'	'	600,000,000	'	'

5_SOFTWARE_Software_Details

5. SOFTWARE - Software (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Intangible assets	$1,257,406	$1,251,406
Accumulated amortization of intangible assets	-545,795	-423,485
Accumulated impairment of assets	-10,000	-10,000
Intangible assets, Net	701,611	817,921
Antree Systems Limited	'	'
Intangible assets	6,000	'
Encryption Software Code	'	'
Intangible assets	15,800	15,800
MediSouth	'	'
Intangible assets	2,500	2,500
Doctors Network of America	'	'
Intangible assets	10,000	10,000
Software License	'	'
Intangible assets	1,200,106	1,200,106
EMR Certification	'	'
Intangible assets	$23,000	$23,000

5_SOFTWARE_Details_Narrative

5. SOFTWARE (Details Narrative) (USD $)	3 Months Ended				6 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Mar. 16, 2013	Mar. 16, 2013
							Antree Systems Limited	Cipher Smith [Member]	Doctors Networkof America [Member]	Doctors Networkof America [Member]	Doctors Networkof America [Member]
											Pending Litigation [Member]
Amortization Expense	$61,155	'	$60,005	'	'	'	'	'	'	'	'
Stock issued Purchase of Asset, Shares	'	200,000	'	100,000	200,000	400,000	200,000	500,004	'	'	'
Stock Issued Purchase of Asset, Value	'	6,000	'	2,800	6,000	13,000	6,000	15,800	'	'	'
Stock Issued, Acquisition, Shares	'	'	'	'	'	'	'	'	500,000	'	'
Shares Issued	'	'	'	'	'	'	'	'	200,000	300,000	'
Shares Issued, Value	'	'	'	'	'	'	'	'	4,000	6,000	'
Amount Due from Acquisition	'	'	'	'	'	'	'	'	'	'	$200,000

6_DISCONTINUED_OPERATIONS_Disc

6. DISCONTINUED OPERATIONS - Discontinued Operations (Details) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2013
Accounts payable	$699,559	'	$699,559	'	$361,994
Net liabilities of discontinued operations	42,873	'	42,873	'	35,356
Revenues	105,118	174,214	222,675	323,571	'
Cost of sales	61,155	61,155	122,310	121,160	'
Operating expenses	1,136,142	279,454	1,388,218	438,325	'
Gain from write-off of debt	'	'	'	-58,984	'
Discontinued Operations [Member]	'	'	'	'	'
Accounts payable	42,837	'	42,837	'	35,356
Net liabilities of discontinued operations	42,837	'	42,837	'	35,356
Revenues	53,766	900	131,050	900	'
Cost of sales	'	'	'	'	'
Operating expenses	-50,568	-938	-138,567	-938	'
Gain from write-off of debt	'	'	'	58,984	'
Income (loss) from discontinued operations	$3,198	($38)	($7,517)	$58,946	'

6_DISCONTINUED_OPERATIONS_Deta

6. DISCONTINUED OPERATIONS (Details Narrative) (USD $)	12 Months Ended
6. DISCONTINUED OPERATIONS (Details Narrative) (USD $)	Sep. 30, 2011
Discontinued Operations and Disposal Groups [Abstract]	'
Sale of Assets, Purchase Price	$100,000

7_LINES_OF_CREDIT_Details_Narr

7. LINES OF CREDIT (Details Narrative) (USD $)	6 Months Ended
7. LINES OF CREDIT (Details Narrative) (USD $)	Mar. 31, 2014
Mutualof Omaha [Member]	'
Revolving Line of Credit, Borrowing Capacity	$65,000
Line of Credit Interest Rate	4.00%
Line of Credit, Amount Outstanding	50,000
Chase [Member]	'
Revolving Line of Credit, Borrowing Capacity	50,000
Line of Credit Interest Rate	4.25%
Line of Credit, Amount Outstanding	$18,370

8_DEBT_MITIGATION_PROGRAM_Debt

8 - DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) (USD $)	6 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Total debt mitigation program	$59,704		$58,984
Gain on write-off of debt	'		-58,984
Additional paid-in capital	59,704	[1]	'	[1]
Accounts Payable and Accrued Expenses	'		'
Total debt mitigation program	59,704		58,984
Accrued Interest	'		'
Total debt mitigation program	'		'

[1]	All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

8_DEBT_MITIGATION_PROGRAM_Deta

8. DEBT MITIGATION PROGRAM (Details Narrative) (USD $)	6 Months Ended
8. DEBT MITIGATION PROGRAM (Details Narrative) (USD $)	Mar. 31, 2014		Mar. 31, 2013
OTHER INCOME (EXPENSE)	'		'
Gain on the Write-Off of Liabilities	'		$58,984
Additional Paid-In Capital for Related Party Liabilities	$59,704	[1]	'	[1]

[1]	All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

9_COMMITMENTS_AND_CONTINGENCIE1

9. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Rent Expense	$0	$0	$0	$0
Payable Write Offs	'	'	$59,704	$58,984

10_RELATED_PARTY_TRANSACTIONS_

10. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
10. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Related Party Transactions [Abstract]	'	'	'	'
Repayment of Advances from Related Parties	'	($25,591)	'	($25,591)

11_EQUITY_Details_Narrative

11. EQUITY (Details Narrative) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
11. EQUITY (Details Narrative) (USD $)	2-May-14	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2013
Common Stock, Shares Authorized	'	'	'	650,000,000	'	650,000,000
Preferred Stock Shares Authorized	'	'	'	4,000,000	'	4,000,000
Common Stock, Par Value	'	'	'	$0.01	'	$0.01
Preferred Stock, Par Value	'	'	'	$0.01	'	$0.01
Preferred Stock, Shares Issued	'	'	'	4,000,000	'	4,000,000
Preferred Stock Shares Outstanding	'	'	'	4,000,000	'	4,000,000
Preferred Stock, Voting Rights	'	'	'	'	'	'150
Preferred Stock, Trading Price of the Common Stock	'	'	'	'	'	$0.01
Compensation Expense	'	'	'	'	'	$38,000
Stock Issued for Cash, Shares	'	'	'	35,000	197,500	'
Stock Issued for Cash, Value	'	'	'	15,000	141,000	'
Stock Issued for Software Licensing and Subscription Agreements, Shares	'	'	'	220,000	300,000	'
Stock Issued for Software Licensing and Subscription Agreements, Value	'	'	'	5,700	9,350	'
Stock Issued for Assets Acquisition, Shares	'	200,000	100,000	200,000	400,000	'
Stock Issued for Assets Acquisition, Value	'	6,000	2,800	6,000	13,000	'
Stock Issued for Replacement, Shares	'	'	'	'	'	180,000
Stock Issued for Services, Shares	1,427,506	'	'	31,750,000	827,000	'
Stock Issued for Services, Value	$30,684	'	'	$666,750	$28,155	'
Antree Systems Limited	'	'	'	'	'	'
Stock Issued for Replacement, Shares	'	'	'	'	'	160,000
Kimberly Ilicerl	'	'	'	'	'	'
Stock Issued for Replacement, Shares	'	'	'	'	'	20,000

12_SUBSEQUENT_EVENTS_Details_N

12. SUBSEQUENT EVENTS (Details Narrative) (USD $)	1 Months Ended	6 Months Ended
12. SUBSEQUENT EVENTS (Details Narrative) (USD $)	2-May-14	Mar. 31, 2014	Mar. 31, 2013
Subsequent Events [Abstract]	'	'	'
Stock Issued for Services, Shares	1,427,506	31,750,000	827,000
Stock Issued for Services, Value	$30,684	$666,750	$28,155